NYSE:CTST - CannTrust Stock Price, Forecast & News

CannTrust trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTST."

CannTrust is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for CannTrust.

8 brokerages have issued 1 year target prices for CannTrust's stock. Their forecasts range from C$2.00 to C$7.00. On average, they anticipate CannTrust's share price to reach C$4.50 in the next year. This suggests a possible upside of 324.5% from the stock's current price. View Analyst Price Targets for CannTrust.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CannTrust in the last year. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for CannTrust.

Press coverage about CTST stock has been trending somewhat negative on Monday, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. CannTrust earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for CannTrust.

CannTrust saw a decline in short interest in December. As of December 13th, there was short interest totalling 12,050,000 shares, a decline of 8.2% from the November 28th total of 13,120,000 shares. Based on an average trading volume of 1,970,000 shares, the short-interest ratio is currently 6.1 days. Currently, 10.1% of the shares of the company are short sold. View CannTrust's Current Options Chain.

Some companies that are related to CannTrust include AC Immune (ACIU), Kadmon (KDMN), Morphic (MORF), Crinetics Pharmaceuticals (CRNX), Magenta Therapeutics (MGTA), Kura Oncology (KURA), MacroGenics (MGNX), Prothena (PRTA), Milestone Pharmaceuticals (MIST), Atreca (BCEL), Neoleukin Therapeutics (NLTX), BioDelivery Sciences International (BDSI), Axovant Sciences (AXON), Molecular Templates (MTEM) and Clovis Oncology (CLVS).

Based on aggregate information from My MarketBeat watchlists, some companies that other CannTrust investors own include Aurora Cannabis (ACB), Canopy Growth (CGC), Aphria (APHA), KushCo (KSHB), Cronos Group (CRON), Aurora Cannabis (ACB), OrganiGram (OGI), HEXO (HEXO), Nokia Oyj (NOK) and Aphria (APHA).

Shares of CTST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CTST stock can currently be purchased for approximately C$1.06.

CannTrust has a market capitalization of C$149.98 million and generates C$35.22 million in revenue each year. The company earns C$-10,460,000.00 in net income (profit) each year or C($0.11) on an earnings per share basis. CannTrust employs 576 workers across the globe.View Additional Information About CannTrust.

The official website for CannTrust is http://www.canntrust.ca/.

CannTrust's mailing address is 3280 LANGSTAFF ROAD UNIT 1, VAUGHAN A6, L4K 4Z8. The company can be reached via phone at 64-7872-2300 or via email at [email protected]